Omics technologies in the diagnosis of oncological diseases
E. N. Loginova,
E. A. Kirch,
E. A. Lyalyukova,
I. V. Druk,
G. I. Nechaeva,
O. Yu. Korennova,
A. A. Semenkin https://doi.org/10.31146/1682-8658-ecg-211-3-69-73
Abstract
High mortality and disability from cancer remains one of the important and unresolved issues of modern medicine. Experts of WHO consider, that cancer is the second leading cause of death worldwide. Approximately 9 million people die of cancer each year, and more than 14 million are diagnosed with cancer. At the same time, according to Russian epidemiology, there is a trend to increase of cases of cancer, including people of young working age, and there is no reliable, verified information about the causes and mechanisms of development of tumor cells. The patient may begin to complain too late, so it is not always possible to suspect this and prevent the diseases. Many research centers and clinics are concerned about this problem and are deeply involved in solving it. To date, a promising direction in the diagnosis of oncological diseases are omics technologies, which are being studied, tested and gradually introduced into modern medicine. According to scientists, the future of healthcare lies with omics technologies, since they allow studying the whole patient’s genotype, which will allow to suggest a person’s predisposition to a particular disease very early, develop methods of correction and prevention, and select the most effective methods of treatment. The purpose of this review is to systematize domestic and foreign data on the current results of the use of omics technologies in the early diagnosis of oncological diseases.
About the Authors
E. N. Loginova
Omsk State Medical University
Russian Federation
Russian Federation
E. A. Kirch
Omsk State Medical University
Russian Federation
Russian Federation
E. A. Lyalyukova
Omsk State Medical University
Russian Federation
Russian Federation
I. V. Druk
Omsk State Medical University
Russian Federation
Russian Federation
G. I. Nechaeva
Omsk State Medical University
Russian Federation
Russian Federation
O. Yu. Korennova
Omsk State Medical University
Russian Federation
Russian Federation
A. A. Semenkin
Omsk State Medical University
Russian Federation
Russian Federation
References
1. Ziegler A, Koch A, Krockenberger K, et al. Personalized medicine using DNA biomarkers: a review. Hum Genet.2012;131(10):1627-1638. doi: 10.1007/s00439-012-1188-9.
2. Bujak R., Struck-Lewicka W., Markuszewski M. J., et al. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal. 2015;113:108-120. doi: 10.1016/j.jpba.2014.12.017.
3. Maliepaard M., Nofziger C., Papaluca M., et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov. 2013;12(2):103-115. doi: 10.1038/nrd3931.
4. Olivier M, Asmis R, Hawkins G. A., et al. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.Int J Mol Sci. 2019;26;20(19):4781 doi: 10.3390/ijms20194781.
5. Terekhova A. A., Nelyubina E. G., Bobkova E. Yu., et al. [Omix technologies: true or false? Paradigm.]. 2019;(2):179-183. (in Russ.)@@ Терехова А. А., Нелюбина Е. Г., Бобкова Е. Ю. и др. Омиксные технологии: правда или быль? Парадигма. 2019;(2):179-183.
6. Wake D. T., Ilbawi N., Dunnenberger H. M., et al. Pharmacogenomics: Prescribing Precisely. Med Clin North Am. 2019;103(6):977-990. doi: 10.1016/j.mcna.2019.07.002.
7. Paltsev M. A., Kvetnoy I. M., Polyakova V. O. et al. Signal molecules: place and role in personalized diagnosis, treatment and prevention of socially significant diseases. Molecular medicine. 2012;(5):3-8. (in Russ.)@@ Пальцев М. А., Кветной И. М., Полякова В. О. и др. Сигнальные молекулы: место и роль в персонифицированной диагностике, лечении и профилактике социально значимых заболеваний. Молекулярная медицина. 2012;(5):3-8.
8. Goetz L.H, Schork N. J. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018 Jun;109(6):952-963. doi: 10.1016/j.fertnstert.2018.05.006
9. Paltsev M. A., Chemezov A. S., Linkova N. S. et al. Omics technology: the role and significance for personalized medicine. Molecular medicine. 2019(4):3-8. (in Russ.) doi: 10.29296/24999490-2019-04-01.@@ Пальцев М. А., Чемезов А. С., Линькова Н. С. И др. Омиксные технологии: роль и значение для развития персонализированной медицины. Молекулярная медицина. 2019(4):3-8. doi: 10.29296/24999490-2019-04-01.
10. Cheng T, Zhan X. Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J. 2017;9;8(1):51-60. doi: 10.1007/s13167-017-0083-9.
11. John A, Qin B, Kalari K. R., et al. Patient-specific multi-omics models and the application in personalized combination therapy. Future Oncol. 2020;16(23):1737-1750. doi: 10.2217/fon-2020-0119.
12. Di Paolo A., Sarkozy F., Ryll B., et al. Personalized medicine in Europe: not yet personal enough? BMC Health Serv Res. 2017;17(1):289.Published 2017.19. doi: 10.1186/s12913-017-2205-4.
13. Del Giacco L, Cattaneo C.Introduction to genomics. Methods Mol Biol. 2012;823:79-88. doi: 10.1007/978-1-60327-216-2_6.
14. Aslam B., Basit M., Nisar M. A., et al. Proteomics: Technologies and Their Applications. J Chromatogr Sci. 2017;55(2):182-196. doi: 10.1093/chromsci/bmw167.
15. Yoo B. C, Kim K. H, Woo S. M., et al. Clinical multi-omics strategies for the effective cancer management. J Proteomics. 2018;30;188:97-106. doi: 10.1016/j.jprot.2017.08.010.
16. Zhukov N. V., Zaretskiy A. R., Lukianov S. A., et al. Study of circulating tumor DNA (liquid biopsy). Prospects for use in oncology. Oncohematology. 2014;4:28-36. (in Russ.)@@ Жуков Н. В., Зарецкий А. Р., Лукьянов С. А., и др. Исследование циркулирующей опухолевой ДНК (жидкая биопсия). Перспективы использования в онкологии. Онкогематология. 2014;4:28-36.
17. Cheung A. H., Chow C., To K. F. Latest development of liquid biopsy. J Thorac Dis. 2018;10 (Suppl 14): S1645-S1651. doi: 10.21037/jtd.2018.04.68.
18. Manak N. A. Personalized and translational medicine: new approaches to treatment. Healthcare. 2014;9:41-5. (in Russ.)@@ Манак Н. А. Персонализированная и трансляционная медицина: новые подходы к лечению. Здравоохранение. 2014;9:41-5.
19. Aushev V. N. MicroRNAs: Small molecules with big value. Clinical oncohematology. 2015;8(1):1-12. (in Russ.)@@ Аушев В. Н. МикроРНК: малые молекулы с большим значением. Клиническая онкогематология. 2015;8(1):1-12.
20. Raschellà G, Melino G, Gambacurta A. Cell death in cancer in the era of precision medicine. Genes Immun. 2019;20(7):529-538. doi: 10.1038/s41435-018-0048-6.
21. Tebani A, Afonso C, Marret S., et al. Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations.Int J Mol Sci. 2016;14;17(9):1555. doi: 10.3390/ijms17091555.
22. Tlegenov A. Sh., Bogenbay G. A. Prospects for the introduction of OMICS technologies for personalized medicine. Bulletin of KazNMU. 2017;1:160-2. (in Russ.)@@ Тлегенов А. Ш., Богенбай Г. А. Перспективы внедрения ОМИКС-технологий персонализированной медицины. Вестник КазНМУ.2017;1:160-2.)
23. Tlegenov A. Sh., Abylayuly Zh., Bogenbay G. A. Metabolic research: a clinician’s perspective. Bulletin of KazNMU. 2017;1:158-60. (in Russ.)@@ Тлегенов А. Ш., Абылайулы Ж., Богенбай Г. А. Метаболомические исследование: взгляды клинициста. Вестник КазНМУ.2017;1:158-60.
24. Johnson J. A. Pharmacists should jump onto the clinical pharmacogenetics train. Am J Health Syst Pharm. 2016;73(23):2013-2016. doi: 10.2146/ajhp160046.
25. Barysheva V. O., Ketova G. G. Personalized medicine: the implementation of pharmacogenetics in practice. Continuing medical education and science. 2016;11(1):4-7. (in Russ.)@@ Барышева В. О., Кетова Г. Г. Персонализированная медицина: реализация фармакогенетики в практике. Непрерывное медицинское образование и наука. 2016;11(1):4-7.)
26. Khokhlov A. L., Yavorskiy A. N., Pozdnyakov N. O. et al. Clinical and genetic aspects of therapy of patients with atherosclerosis. Archives of Internal Medicine. 2018;1:45-51. (in Russ.)@@ Хохлов А. Л., Яворский А. Н., Поздняков Н. О., и др. Клинико-генетические аспекты терапии пациентов с атеросклерозом. Архив внутренней медицины. 2018;1:45-51.
27. Panoutsopoulou K., Avgeris M., Scorilas A. MiRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. Expert of Molecular Diagnostics. 2018. doi: 10.1080/14737159.2019.1673732.
Review
For citations:
Loginova E.N., Kirch E.A., Lyalyukova E.A., Druk I.V., Nechaeva G.I., Korennova O.Yu., Semenkin A.A. Omics technologies in the diagnosis of oncological diseases. Experimental and Clinical Gastroenterology. 2023;(3):69-73. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-211-3-69-73
Views:
416
Email this article 